SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as a significant validation of its platform technology across potential new disease areas. The community is actively discussing the potential for upfront payments, substantial milestones, and royalties, while also looking for further partnerships, particularly for its advanced COVID-Flu combination vaccine. This recent strategic move, alongside the company's strengthened financial position, is generating optimism about future growth despite ongoing activist investor pressure.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending as discussions erupt over former President Trump's threats of new tariffs on European nations, stemming from their stance on Greenland and his apparent frustrations regarding the Nobel Peace Prize. This has ignited heated debate among the community, with many expressing concern over potential market instability and strained international relations, while supporters view these actions as beneficial for "America First" economic policies.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is seeing heightened volatility as President Trump's escalating tariff threats against NATO allies, particularly concerning Greenland, spark widespread geopolitical uncertainty. Community sentiment is sharply divided, with some anticipating a deeper market correction while others view the current downturn as a 'buy the dip' opportunity amidst global bond market concerns and a notable rise in precious metal prices. Investors are closely monitoring a potential Supreme Court ruling on tariffs as a key market mover.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community closely follows its ongoing interactions with the FDA regarding the Biologics License Application for its Duchenne muscular dystrophy treatment, deramiocel, and the forthcoming submission of the full HOPE-3 clinical study report. Sentiment is divided, with many expressing strong bullishness and anticipating significant upside potential, while others voice concerns over perceived delays and discuss potential market manipulation, as analysts reiterate positive ratings for the company.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to highly positive Phase 1 clinical trial results for its drug, soquelitinib, in treating moderate to severe atopic dermatitis. This early data, especially in patients resistant to other treatments, is fueling community excitement about its potential as a significant new option in a large market, with discussions also revolving around the possibility of strategic partnerships or a buyout, alongside concerns about the drug's early development stage.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is experiencing significant volatility amid escalating geopolitical tensions, notably the US asserting control over Venezuela's oil and ongoing debates surrounding US tariffs, fueling a "flight to quality" narrative for some. The community is actively discussing whether these events, alongside large institutional bond purchases, will continue to boost Treasuries as a safe haven or intensify concerns over US debt and the Federal Reserve's independence.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is experiencing significant volatility and trending discussions following a critical report alleging financial misconduct, compounded by broader weakness in the tech sector. While many in the community are dismissing the report as rehashed FUD and market manipulation, bulls are highlighting the company's strong AI-powered ad platform and anticipated robust Q4 earnings. This has fueled a sharp debate between those buying the dip and bears reacting to the serious claims, driving notable price swings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending due to regulatory clarity for ANKTIVA's resubmission for papillary bladder cancer, requiring no new clinical trials, coupled with expanding international approvals. The community is actively discussing the potential for a significant short squeeze, driven by high short interest and exceptional volume, as many investors embrace the long-term "cancer cure" narrative. This optimism persists even as the broader market faces headwinds, highlighting IBRX's standout performance and promising pipeline.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is currently experiencing a significant surge, fueled by an intense Arctic air invasion across the United States that is driving up natural gas demand and futures prices. The strong upward momentum has triggered a notable short squeeze, with the community actively discussing substantial profits and anticipating continued upside as extreme cold weather is projected to persist. This volatility is characteristic of the 2x leveraged ETF, attracting both profit-takers and those eyeing further gains.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending ahead of its upcoming earnings, with community focus on its recent all-cash bid for Warner Bros. Discovery assets and a prominent figure's bond purchases. Bulls anticipate a significant rebound for the perceived oversold stock, highlighting its "tariff-proof" nature amidst a broader red market. Bears, however, warn of further downside, viewing the deal as a potential drag and suggesting market volatility around the report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UWM Holdings (UWMC) stock garnered retail attention after Keefe Bruyette upgraded the stock to “Outperform” from “Underperform.”According to The Fly, the brokerage also raised the stock’s price target to $7.50 from $6.50. The new price target implies a 19.4% upside to the stock’s last closing price.The Keefe Bruyette analyst noted that the stock’s 5% selloff following its fourth-quarter earnings was ‘overdone.’According to FinChat data, the company posted a net income of $0.02 per share for the fourth quarter, compared with Wall Street’s estimated $0.08 per share, in February.While Federal Reserve rate cuts helped lower mortgage rates in September, they began to rise again towards the end of 2024 on inflation worries.UWM’s loan originations rose to $38.7 billion during the fourth quarter, from $24.4 billion in the year-ago quarter.The analyst said that UWM is positioned to be one of the primary beneficiaries of a normalizing mortgage market given its dominant position in the purchase market and increasing share in the refinance market.As per TheFly, Keefe Bruyette also viewed UWM more favorably than its peer Rocket Companies, which <a href="https://stocktwits.com/news-articles/markets/equity/rocket-companies-stock-rises-after-q4-profit-beat/chdgfwrRyr">had topped</a> Wall Street’s estimates for quarterly profit last week.Retail sentiment about UWM on Stocktwits remained in the ‘extremely bullish’ (85/100) territory, while retail chatter remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:804/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/UWMC_Mar_2_84ba3adc96.JPG" alt="UWMC’s Sentiment Meter and Message Volume as of 12:33 a.m. ET on March 3, 2025 | Source: Stocktwits" width="804" height="177"><figcaption>UWMC’s Sentiment Meter and Message Volume as of 12:33 a.m. ET on March 3, 2025 | Source: Stocktwits</figcaption></figure>According to FinChat data, the stock has a 12 month consensus price target of $6.72.Last week, another brokerage, BTIG, viewed the selloff as temporary and said it was due to an expense-driven quarterly earnings miss, which is less impactful than a decline in demand.<a href="https://stocktwits.com/symbol/UWMC">UWM shares</a> have gained marginally over the past year, but they have fallen by 5.4% over the past three months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/shell-reportedly-mulls-chemical-asset-sales-in-us-europe/che0chbRz1">Shell Reportedly Mulls Chemical Asset Sales In US, Europe — Will It Sway Retail Bears?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the UWM Holdings Corporation company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

UWM Holdings Stock In Spotlight After Keefe Bruyette Upgrade, Retail Stays Enthusiastic

The brokerage noted that the stock’s 5% selloff following its fourth-quarter earnings was ‘overdone’ according to TheFly.

PP
TIDAL ETF TRUST II - The Meet Kevin Pricing Power ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PP News

PPTIDAL ETF TRUST II - The Meet Kevin Pricing Power ETF